Product Pathways - Translational Control
SignalSilence® RMP siRNA II #6495
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.
Western blot analysis of extracts from HeLa cells, transfected with 100 nM SignalSilence® Control siRNA (Unconjugated) #6568 (-), SignalSilence® RMP siRNA I #6464 (+) or SignalSilence® RMP siRNA II (+), using RMP Antibody #5844 (upper) or α-Tubulin (11H10) Rabbit mAb #2125 (lower). The RMP Antibody confirms silencing of RMP expression, while the α-Tubulin (11H10) Rabbit mAb is used as a loading control.
SignalSilence® RMP siRNA II from Cell Signaling Technology (CST) allows the researcher to specifically inhibit RMP expression using RNA interference, a method whereby gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. All SignalSilence® siRNA products from CST are rigorously tested in-house and have been shown to reduce target protein expression by western analysis.
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
CST recommends transfection with 100 nM RMP siRNA II 48 to 72 hours prior to cell lysis. For transfection procedure, follow protocol provided by the transfection reagent manufacturer. Please feel free to contact CST with any questions on use.
Each vial contains the equivalent of 100 transfections, which corresponds to a final siRNA concentration of 100 nM per transfection in a 24-well plate with a total volume of 300 μl per well.
RMP (RPB5-Mediating Protein), also known as URI (Unconventional prefoldin RBP5 Interactor), was described as an unconventional member of the prefoldin (PFD) family of chaperones that are involved in actin and tubulin folding (1-4). Like conventional members of the α-class of PFDs, RMP contains N- and C-terminal α-helical coiled-coil structures connected by two β hairpins. In addition, RMP possesses an RPB5-binding segment and a long C-terminal acidic segment. It is posited that RMP exists as a component of a macromolecular complex within human cells and functions as a molecular scaffold to assemble a PFD complex containing other PFDs and proteins with functions in transcription and ubiquitination. Indeed, evidence is provided that RMP negatively modulates RNA polymerase II-dependent transcription by binding to TFIIF (5) and RBP5 (6) and is involved in mTOR signaling by coordinating the regulation of nutrient availability with gene expression (1). In accord with its ability to coordinate gene expression with nutrient availability, RMP was shown to be a mitochondrial substrate of S6K1. S6K1-mediated phosphorylation of RMP at Ser371 triggers a series of biochemical events that constitute a negative feedback loop, in part, aimed at restraining S6K1 survival signaling and ensuring that the mitochondrial threshold for apoptosis corresponds to availability of nutrients and growth factors (7).
- Gstaiger, M. et al. (2003) Science 302, 1208-12.
- Vainberg, I.E. et al. (1998) Cell 93, 863-73.
- Martín-Benito, J. et al. (2002) EMBO J 21, 6377-86.
- Geissler, S. et al. (1998) EMBO J 17, 952-66.
- Wei, W. et al. (2003) Cell Res 13, 111-20.
- Dorjsuren, D. et al. (1998) Mol Cell Biol 18, 7546-55.
- Djouder, N. et al. (2007) Mol Cell 28, 28-40.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
- 6568 SignalSilence® Control siRNA (Unconjugated)
- 6201 SignalSilence® Control siRNA (Fluorescein Conjugate)
- 6464 SignalSilence® RMP siRNA I
- 5844 RMP Antibody
Limited Use Label License, RNA interference: This product is licensed under European Patent 1144623 and foreign equivalents from Ribopharma AG, Kulmbach, Germany and is provided only for use in non-commercial research specifically excluding use (a) in drug discovery or drug development, including target identification or target validation, by or on behalf of a commercial entity, (b) for contract research or commercial screening services, (c) for the production or manufacture of siRNA-related products for sale, or (d) for the generation of commercial databases for sale to Third Parties. Information about licenses for these and other commercial uses is available from Ribopharma AG, Fritz-Hornschuch-Str. 9, D-95326 Kulmbach, Germany.
For Research Use Only. Not For Use In Diagnostic Procedures.